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Aims Patient-centred outcomes can be measured with different instruments. We compared the performance of two health-




Patients who were admitted for elective CABG in Kuopio University Hospital Finland in 2012–14 and had completed
both instruments concurrently as part of the admission process (n ¼ 182). Follow-up was conducted by postal survey
12 months after the CABG operation. The validity, agreement, and responsiveness to change of both instruments were
examined. The mean baseline HRQoL index scores obtained by the EQ-5D and the 15D were 0.795 and 0.859, re-
spectively (P, 0.001 for difference). The agreement between instruments was poor (Spearman’s rho ¼ 0.449;
P, 0.001). Observed ceiling effects at baseline for the EQ-5D and 15D were 31.9 and 4.4%, respectively. EQ-5D
was able to discriminate distinct Canadian Cardiovascular Society groups. During the 1-year follow-up, clinically im-
portant improvement was observed in 39.6 and 53.3% of patients with the EQ-5D and the 15D, respectively. However,
with the 15D, the number of operated patients required to produce one additional quality-adjusted life year (QALY)
was more than twice as high compared with the EQ-5D.
Conclusion EQ-5D and 15D do not appear to be interchangeable when patient-centred outcomes in CABG patients are assessed.
The EQ-5D seems to have better discriminative power and known-group validity, whereas the 15D is more sensitive to
change over time. These instruments lead to significantly different estimates concerning the number of QALYs gained.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Coronary disease † Revascularization † Coronary artery bypass graft surgery
Introduction
Coronary artery disease (CAD) is a common and costly disease. In
developed countries, it causes approximately one-fourth of all
deaths. It can be treated with revascularization either by coronary
artery bypass grafting (CABG) or percutaneous coronary inter-
vention, or by conventional pharmacotherapy.1 CABG is generally
preferred for patients with left main CAD or more advanced
disease.2– 8
After a cardiac intervention, outcomes are commonly evaluated
in terms of mortality, complications, recurrence of symptoms, or
changes in functional capacity, as all of them can be measured rela-
tively easily. However, in the era of patient-centred healthcare, also
patient-reported outcomes such as changes in physical, psychological,
and social functioning are deemed important. In addition, as survival
rates have improved significantly, survival alone is no longer the only
goal of treatment and health-related quality of life (HRQoL) also plays
an essential role.9
* Corresponding author. Tel: +358 50 362 3058, Fax: +358 17 162 131, Email: jari.heiskanen@uef.fi
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2016. For permissions please email: journals.permissions@oup.com.
European Heart Journal – Quality of Care and Clinical Outcomes (2016) 2, 193–200
doi:10.1093/ehjqcco/qcw002
Currently, there are several preference-based HRQoL measures,
such as the SF-6D,10 HUI3,11 EQ-5D,12,13 and the 15D,14 – 16 that
provide a descriptive health state profile and a utility score of overall
HRQoL. The EQ-5D appears to be currently the most frequently
used preference-based instrument worldwide,17 whereas the 15D
is a widely used HRQoL instrument in Finnish hospitals. Both of
these instruments provide single utility scores that can be applied
to the estimation of quality-adjusted life years (QALYs). The
QALY concept is widely used to assess the value for money of
health technologies and one of its main advantages is that it
combines both survival and HRQoL benefits of treatments in a
single indicator.
The EQ-5D has been compared against other HRQoL mea-
sures,18,19 but studies comparing the EQ-5D and 15D are less com-
mon. To our knowledge, only one previous study has assessed the
similarity between the EQ-5D and 15D scales in patients undergoing
elective CABG.20 Moreover, little is known on how the selection of
HRQoL instruments is related to clinically meaningful changes in
HRQoL and the number of QALYs gained in this same patient
group. Therefore, the purpose of the present study was to explore
the similarities and differences of the EQ-5D and 15D instruments in
measuring patient-centred outcomes (in terms of HRQoL) of elect-
ive CABG. The comparison was made based on validity, degree of
agreement, responsiveness, percentage of patients with a clinically
meaningful change in HRQoL, and the number of QALYs gained
during the 1 year of follow-up.
Methods
Study design and setting
The present study was an observational, methodological study con-
ducted as a part of routine clinical practice. Study participants were
recruited from the Heart Center of the Kuopio University Hospital,
Kuopio, Finland. The recruitment of patients took place as part of
routine clinical practice from 2012 to 2014. Patients admitted for
CABG operation were asked to complete both the EQ-5D and 15D
instruments concurrently as part of the preoperative hospital admission
process. Follow-up was conducted by postal survey 12 months after the
operation. To enable comparison of the responsiveness of the two
instruments, only respondents fully completing both questionnaires at
baseline and at 12 months were included in this study. The demographic
and preoperative characteristics of patients were extracted from elec-
tronic patient records and linked with the outcome measurements by
applying personal identification numbers. All personal identifiers were
removed from the final dataset. The study was approved by the ethics
committee of the Kuopio University Hospital.
Health-related quality-of-life instruments
The EQ-5D measures mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression and is a widely used, self-administrated,
generic, five-dimension questionnaire for assessing HRQoL. Each di-
mension includes three ordinal categories of severity corresponding
to no, moderate, or severe problems. Combining one level from each
dimension defines 243 different health states ranging from 11111 (full
health) to 33333 (worst health). These health states are converted
into a single index score representing health utilities (20.59 to 1.00),
using valuations elicited from a sample of the general public. In the
present study, the time-trade off (TTO) valuation based on samples
of the United Kingdom (UK) general public was applied.12,13
The 15D instrument is also a generic, self-administrated questionnaire
for measuring HRQoL. It consists of 15 dimensions (mobility, vision, hear-
ing, breathing, sleeping, eating, speech, excretion, usual activities, mental
function, discomfort and symptoms, depression, distress, vitality, and sex-
ual activity) with five ordinal levels. The single index score of the 15D
instrument ranges from 0 to 1. The 15D instrument can generate over
30 billion different health states, and is generated from a set of utility or
preference weights. The valuation system of the 15D used in this study is
based on a set of Finnish population-based preferences.14–16
Statistical analyses
Baseline demographic data are presented using percentages, means
and standard deviations as appropriate. Due to skewed distribution
of HRQoL scores, non-parametric tests were applied. Differences be-
tween the instruments at baseline were tested by the Wilcoxon
signed-rank test. The ceiling effects of the EQ-5D and 15D were as-
sessed by computing the percentage of respondents reporting full
health at baseline or at the 12 months. The HRQoL data were re-
ported as means and confidence intervals at baseline and at 12-month
follow-up. A non-parametric bootstrap procedure, based on 100 repli-
cations, was performed to estimate the mean difference and 95% CI
between 12-month changes in EQ-5D and 15D scores. Differences be-
tween instruments were tested by the Wilcoxon signed-rank test. In
addition, the changes in mean scores were categorized and compared
according to minimal important differences (MIDs) reported in the lit-
erature for both instruments. The level of statistical significance is de-
fined as P, 0.05. All statistical analyses were conducted by STATA
12.0 (Stata Corp. LP, Station, TX, USA) and SPSS 19 (IBM SPSS
Statistics).
Construct and discriminant validity
The construct validity of the instruments was assessed by examining
Spearman correlation between the estimated utility scores at baseline.
Discriminant validity was assessed by the known-group method by in-
vestigating whether the EQ-5D and 15D scores are different for prede-
fined distinctive groups. Patients were grouped according to sex, age
(,60, 60–74, and ≥75 years), and functional status at baseline. The
functional status was defined by the Canadian Cardiovascular Society
(CCS) classes for grading angina pectoris.21 The CCS grading system
is analogical with the New York Heart Association grading system.22,23
Classifications were done preoperatively by heart surgeons. Patients
aged ≥75 years and with poorer CCS status were hypothesized to
have lower utility scores for these two instruments.
Agreement
Agreement between the utility instruments was evaluated by concord-
ance correlation coefficient (CCC)24 and the Bland–Altman plot.25 –28
The strength of agreement was considered as poor when CCC ,0.9,
moderate when CCC 0.90–0.95, and strong when CCC .0.99.29 In
the Bland–Altman plot, the differences between the two utility scores
(on the y-axis) were plotted against the average values of these utility
scores (on the x-axis). The deviation of the difference from zero line,
which implies total agreement between the instruments, indicates the
degree of agreement for each patient on the plot.25 –28
Responsiveness
To evaluate the responsiveness to change (i.e. ability to detect changes
in utility scores over time) of the EQ-5D and 15D, the changes from
baseline were estimated. In addition, the change in mean scores were
categorized and compared according to MIDs reported in the literature
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for both instruments. The applied MID limits were 0.074 for the
EQ-5D30,31 and 0.015 for the 15D,32 respectively.
Differences in the responsiveness between the instruments were
compared across patient groups with varying levels of disease severity
to reveal whether the magnitude of instrument discrepancy is related
to the disease severity. The patients were divided into groups according
to their ejection fraction (.50%; normal, ≤50%; mild/moderate reduc-
tion, ,30%; severe reduction), the diagnosis of left main stenosis, the
presence of other comorbidities (i.e. cerebral haemorrhage, central
nervous system disease, kidney disease, lung disease, diabetes, potential
heart failure, and other disease), age (cut-off 75 years), sex, disease
severity (CCS class ≥3), and body mass index (BMI; cut-off 25). Differ-
ences between the predefined groups were tested using Fisher’s exact
test.
Effect of instrument on the number of minimal important
differences and quality-adjusted life years gained
The inverted values of the proportion of patients reaching the MID at 12
months were applied to describe the number of required persons to
reach one positive MID by both instruments. To demonstrate the im-
pact of differences in the EQ-5D and 15D utility scores on the number
of QALYs gained during the 1-year follow-up, the number needed per
QALY gained (NNQ) approach was applied.33 The NNQ is a group-
level estimate for the number of patients that must be operated in order
to gain 1 QALY and thus, it provides a simple and practical metric
to compare the results obtained by two different instruments. The
NNQ was estimated as an inverted value of the utility gain measured
by the EQ-5D and 15D instruments (i.e. 1/mean change from baseline
in utility score at 12 months).
Results
Between years 2012 and 2014, a total of 1018 CABG operations
were conducted in the Kuopio University Hospital. The final study
sample included 182 patients with HRQoL data measured with both
instruments at baseline and at the 12-month follow-up (17.8% of eli-
gible patients). The demographic and preoperative characteristics of
the total population and the present study sample are described in
Table 1. The study participants were slightly younger than the total
population on average. In addition, the proportions of patients in dif-
ferent CCS classes and the prevalence of other clinical conditions
indicated that the sample of study participants represented a patient
group with slightly less severe disease states when compared with
the total population. However, no significant differences in HRQoL
index values between the total and study populations were
observed (Table 1).
At baseline, the mean (95% CI) EQ-5D and 15D scores were
0.795 (0.765–0.826) and 0.859 (0.845–0.874), respectively. Thus,
the 15D produced significantly higher mean baseline scores than
the EQ-5D, with the mean difference (15D minus EQ-5D) (95%
CI) being 0.064 (0.040–0.088) (P, 0.001 for difference). Differ-
ences between the instruments remained across the majority of
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Table 1 Baseline characteristics of the patients
Variables Study population (n5 182) Total population (n 5 1018)
Male, n (%) 148 (81.3) 815 (80.1)
Age, mean (SD) 65.8 (9.6) 67.37 (8.5)
Height, mean (SD) 171.9 (11.2) 170.76 (8.4)
Weight, mean (SD) 83.2 (16.6) 82.00 (15.0)
15D baseline mean index (SD, n) 0.859 (0.099) (n ¼ 182) 0.852 (0.092) (n ¼ 773)
EQ-5D baseline mean index (SD, n) 0.795 (0.207) (n ¼ 182) 0.791 (0.195) (n ¼ 556)
Canadian Cardiovascular Society class, n (%)
1 10 (5.5) 17 (1.7)
2 58 (31.9) 228 (22.4)
3 75 (41.2) 400 (39.3)
4 39 (21.4) 368 (36.1)
Missing 0 (0.0) 5 (0.5)
Ejection fraction, n (%)
≤50 Reduced 58 (31.9) 213 (21.0)
.50 Normal 122 (67.0) 798 (78.4)
Data missing 2 (1.1) 7 (0.7)
Left main stenosis, n (%)
No 152 (83.5) 620 (60.9)
Yes (over 50%) 30 (16.5) 398 (39.1)
Comorbidities, n (%)a
Yes 64 (35.2) 406 (39.9)
No 118 (64.8) 600 (58.9)
Missing 0 (0.0) 12 (1.2)
aCerebral haemorrhage, central nervous system disease, kidney disease, lung disease, diabetes, potential heart failure, and other disease.
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the defined subgroups (Table 2). Neither the 15D, nor the EQ-5D,
exhibited a significant floor effect in this study. However, at baseline,
the ceiling effects for the EQ-5D and the 15D were 31.9 and 4.4%,
respectively.
Construct and discriminant validity
The EQ-5D and 15D produced significantly different baseline utility
scores across different subgroups at baseline. There was a tendency
for lower utility scores among women and older individuals. Only
the EQ-5D was able to discriminate the different CCS classes
(P ¼ 0.039), indicating disease severity at baseline (Table 2).
Agreement between instruments
The CCCs demonstrated poor agreement between the instruments
(Table 2). Figure 1 graphically presents the discrepancy between the
EQ-5D and 15D instruments at baseline. According to the Bland–
Altman plot, the limits of agreement (LOAs) were 20.454 to 0.278
for a mean difference (95% CI) of 0.064 (0.040–0.088), which is
equal to an expected between-measure variation of 0.732 (i.e. a
range between 20.454 and 0.278) for any pair of future baseline
observation (Figure 1). Thus, also the LOA indicated large differ-
ences between these two instruments for individual subjects.
Responsiveness to change
The observed mean changes (95% CI) from baseline to the
12-month follow-up were 0.053 (0.017–0.088) and 0.024 (0.009–
0.038) for the EQ-5D and 15D, respectively (P ¼ 0.024 for
difference). The correlation between 1-year change in EQ-5D and
15D was 0.476, P, 0.001 (Figure 2). When the observed changes
were stratified according to the MID threshold values, the EQ-5D
indicated improvement in 39.6% (95% CI 32.4–46.7%) of the pa-
tients in contrast to the 53.3% (46.0–60.6%) by the 15D.
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Table 2 Baseline scores for the EQ-5D and 15D stratified by the baseline characteristics





Mean utility score difference
between 15D and EQ-5D at
baselinea





Men 148 (81.3) 0.866 0.807 0.059 (P, 0.001) 0.517 (P, 0.001) 0.593 (P, 0.001)
Women 34 (18.7) 0.832 0.743 0.089 (P ¼ 0.081) 0.250 (P ¼ 0.010) 0.651 (P, 0.001)
P-value* 0.056 0.104
Age (years)
,60 43 (23.6) 0.886 0.843 0.042 (P ¼ 0.128) 0.436 (P, 0.001) 0.613 (P, 0.001)
60–74.9 103 (56.6) 0.853 0.776 0.077 (P, 0.001) 0.461 (P, 0.001) 0.690 (P, 0.001)
≥75 36 (19.8) 0.848 0.794 0.053 (P ¼ 0.019) 0.310 (P ¼ 0.020) 0.439 (P ¼ 0.007)
P-value† 0.190 0.193
CCS
1 10 (5.5) 0.903 0.908 20.005 (P ¼ 0.838) 0.385 (P ¼ 0.134) 0.555 (P ¼ 0.096)
2 58 (31.9) 0.873 0.843 0.031 (P ¼ 0.048) 0.543 (P, 0.001) 0.582 (P, 0.001)
3 75 (41.2) 0.851 0.780 0.071 (P, 0.001) 0.488 (P, 0.001) 0.618 (P, 0.001)
4 39 (21.4) 0.846 0.729 0.119 (P ¼ 0.008) 0.357 (P, 0.001) 0.618 (P, 0.001)
P-value† 0.261 0.039
CCC, concordance correlation coefficient; CCS, Canadian Cardiovascular Society.
aAccording to the Wilcoxon signed-rank test.
bConcordance correlation coefficient (CCC), rho.
cSpearman’s and Kendall’s correlations, Spearman’s rho.
*According to the two-sample Wilcoxon rank-sum (Mann–Whitney) test.
†According to the Kruskal–Wallis equality-of-populations rank test.
Figure 1 Bland–Altman plot for EQ-5D and 15D scores at
baseline.
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Furthermore, the EQ-5D indicated no clinically meaningful change
in 45.6% (38.3–52.9%) of the patients as opposed to 22.0%
(15.9–28.1%) by the 15D. A clinically important deterioration was
reported by 14.8% (9.6–20.0%) of the patients with the EQ-5D and
by 24.7% (18.4–31.1%) with the 15D, respectively. The proportions
of changes stratified according to the MID values were significantly
different between the instruments (P, 0.001 for difference).
Significant differences between instruments were systematically
observed when the stratified MIDs were grouped by severity of ill-
ness like left main stenosis, comorbidities, age group (cut-off .75
years), lower than 50% ejection fraction, CCS classes 3 and 4, BMI
(cut-off .25), or sex (Table 3). Both instruments indicated that
poorer preoperative status (i.e. left main stenosis or poor ejection
fraction) was associated with a higher percentage of improved pa-
tients (i.e. patients in whom the change in HRQoL exceed the
MID) when compared with the whole study sample. More interest-
ingly, both instruments also indicated that among a subgroup of pa-
tients aged over 75 years, the relative proportion of improved
patients was lower than in the whole study sample. Although we
did not observe any differences in HRQoL change between men
and women (data not shown), the instruments performed similarly
in women but differently in men.
Effect of instrument on the number
of minimal important differences and
quality-adjusted life years gained
The number of patients needed to be treated to produce one pa-
tient with a positive MID at 12 months was rather similar for both
instruments with no significant differences (Table 4). As summarized
in Table 4, on average, the difference between the numbers of pa-
tients needed to treat was only one. However, the NNQ estimates
demonstrated much wider and significant disagreement between
the instruments. With the 15D, the number of operated patients
required to produce one additional QALY was more than twice
as high compared with the EQ-5D.
Discussion
Our findings show that the reported pre- and postoperative utilities,
as well as proportions of significant quality of life and QALY gains
from a CABG operation, are heavily dependent on the measure
used to elicit them. The EQ-5D produced significantly lower pre-
operative utility scores than the 15D instrument for patients under-
going CABG operation. Among these CABG patients, the EQ-5D
showed better discriminative power as it was able to distinguish
the preoperative CCS classes better than the 15D instrument.
The degree of disagreement between the instruments showed
that the variation between the measures is too great for them to
be considered interchangeable. There are many possible reasons
for these differences in HRQoL measured with EQ-5D and 15D, in-
cluding the dimensions, valuation sets, and applied scales of different
instruments. Our findings are in line with a previous study reporting
only a moderate agreement between the instruments,34 with even
lower utility scores among CAD patients (0.684 with the EQ-5D
and 0.821 with the 15D) than observed in our study.35
As expected, larger 12-month changes from baseline were ob-
served with the EQ-5D than the 15D due to the differences in their
valuation processes and different theoretical scales of measurement.
Actually, the magnitude of the overall utility gain was twice as large
when measured with the EQ-5D compared with the 15D, even if
the EQ-5D produced lower values in general. Thus, when the
15D results were used as the basis for calculating the NNQ roughly
twice as many operated patients were needed to produce one
QALY compared with those obtained with the EQ-5D. In addition,
this difference has also important implications for cost–utility ana-
lyses: similar to previous research, our study shows that the choice
of instrument can have a crucial effect on the results of cost–utility
analysis.34 Thus, vigilance is warranted when deciding which HRQoL
instrument to use.35,36
In daily clinical practice, the proportion of patients reaching the
positive MID may act as a more practical and patient-centred out-
come for monitoring clinical success than the cumulative numbers
of QALYs gained. However, according to our findings, these two
metrics produce conflicting results: the EQ-5D instrument leads
to a larger absolute improvement in the utility score and a higher
number of QALYs gained, but to a smaller proportion of patients
reaching the positive MID than the 15D. Thus, the interpretation
is different when the observed changes in the mean utility scores
are related to the reported MID values of the instruments, i.e. the
15D seems to be more sensitive to change and indicates improve-
ment in health utility more often than the EQ-5D does. Further-
more, our subgroup analyses revealed that if the health status is
better than average, the EQ-5D cannot properly differentiate
changes in the reported health state because of its ceiling effect as
reported previously.37 Thus, in poor health states, the EQ-5D can
indicate very low values, even below zero, which is equivalent to
a health state poorer than death. The EQ-5D responds easily to
poor health states, but at the same time overreacts to good health
by producing easily full index scores. These properties of the EQ-5D
have also been observed earlier in comparison with the SF-6D.38
The results of the study need to be interpreted in light of some
limitations. First, we only included the respondents who had fully
completed both questionnaires at baseline and 12-month follow-up.
Figure 2 Correlation between 1-year change in 15D and
EQ-5D.
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Table 3 Twelve-month changes from baseline measured by the 15D and the EQ-5D in different subgroups
15D (MID 0.015)a, n (%) EQ-5D (MID 0.074)a, n (%) P-values†
All patients
Negative MID change 45 (24.7) 27 (14.8) ,0.001
No MID changes 40 (22.0) 83 (45.6)
Positive MID change 97 (53.3) 72 (39.6)
Total, n 182 182
Age group over 75 years
Negative MID change 15 (41.7) 11 (30.6) 0.002
No MID changes 8 (22.2) 15 (41.7)
Positive MID change 13 (36.1) 10 (27.8)
Total, n 36 36
Sex (female)
Negative MID change 4 (11.8) 6 (17.7) 0.07
No MID changes 11 (32.3) 16 (47.0)
Positive MID change 19 (55.9) 12 (35.3)
Total, n 34 34
Sex (male)
Negative MID change 41 (27.7) 21 (14.2) ,0.001
No MID changes 29 (19.6) 67 (45.3)
Positive MID change 78 (52.7) 60 (40.5)
Total, n 148 148
BMI .25
Negative MID change 33 (25.4) 19 (14.6) ,0.001
No MID changes 29 (22.3) 56 (43.1)
Positive MID change 68 (52.3) 55 (42.3)
Total, n 130 130
Comorbidities
Negative MID change 18 (28.1) 8 (12.5) 0.001
No MID changes 13 (20.3) 28 (43.8)
Positive MID change 33 (51.6) 28 (43.8)
Total, n 64 64
Ejection fraction reduced
Negative MID change 11 (19.0) 5 (8.6) 0.006
No MID changes 9 (15.5) 25 (43.1)
Positive MID change 38 (65.5) 28 (48.3)
Total, n 58 58
Left main stenosis population
Negative MID change 6 (20.0) 2 (6.7) 0.012
No MID changes 5 (16.7) 12 (40.0)
Positive MID change 19 (63.3) 16 (53.3)
Total, n 30 30
CCS class 3 or 4
Negative MID change 30 (26.3) 15 (13.2) 0.001
No MID changes 23 (20.2) 50 (43.9)
Positive MID change 61 (53.5) 49 (43.0)
Total, n 114 114
MID, minimal important difference; BMI, body mass index; CCS, Canadian Cardiovascular Society.
aBased on literature.27–29
†Fisher’s exact test.
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This might increase the risk of selection bias and limit the generaliz-
ability of our results. However, the characteristics of those included
in the study sample (n ¼ 182) were comparable to the eligible popu-
lation (i.e. those undergoing CABG), suggesting that the results are
generalizable to the target population (i.e. those undergoing
CABG). One potential limitation is also the use of the scoring sys-
tem of the EQ-5D which is based on the UK TTO system. However,
there is no local TTO algorithm available for the EQ-5D in Finland,
and therefore UK TTO valuations have also been applied in a previ-
ous Finnish study.35 One limitation is also that we did not apply the
newer EQ-5D-5L version in the present study, even if it has been
shown to be promising compared with the EQ-5D-3L version in
terms of a lower ceiling effect, better discriminatory power, and
known-groups validity.39 However, currently, the country-specific
value sets for the new EQ-5D-5L are lacking for many countries.
Therefore, the use of the newer EQ-5D version is limited until
country-specific value sets are developed.
As it may be too optimistic to hope that healthcare providers will
reach a consensus regarding which instruments to use for measure-
ment of patient-centred outcomes in terms of HRQoL, it is not un-
reasonable to expect that at least the applied HRQoL instruments
and methods are clearly and transparently stated when patient-
centred outcome studies are reported. Otherwise, there will be a
lot of data that are non-comparable and unusable for the compari-
son of different hospitals. Even in the case of one hospital and one
disease, it is necessary to raise awareness of the different perform-
ance of HRQoL instruments to ensure rational decision-making,
although the choice of the HRQoL instrument may well be based
on study objectives as previously suggested.40
Conclusion
In CABG patients, the EQ-5D seems to have better discriminative
power and known-group validity, whereas the 15D is more sensitive
to change over time. The use of these instruments in the estimation
of QALYs gained leads to significantly different estimates. Overall,
the EQ-5D and 15D do not appear to be interchangeable.
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